HUP0301453A2 - Eletriptánt tartalmazó, szigmoid görbe szerinti, szabályozott hatóanyag-leadású, szemcsés kompozíció és eljárás az előállítására - Google Patents

Eletriptánt tartalmazó, szigmoid görbe szerinti, szabályozott hatóanyag-leadású, szemcsés kompozíció és eljárás az előállítására

Info

Publication number
HUP0301453A2
HUP0301453A2 HU0301453A HUP0301453A HUP0301453A2 HU P0301453 A2 HUP0301453 A2 HU P0301453A2 HU 0301453 A HU0301453 A HU 0301453A HU P0301453 A HUP0301453 A HU P0301453A HU P0301453 A2 HUP0301453 A2 HU P0301453A2
Authority
HU
Hungary
Prior art keywords
eletriptan
controlled release
preparation
showing
particulate composition
Prior art date
Application number
HU0301453A
Other languages
English (en)
Inventor
Manaud Pierre Frederick De Raspide
Ross James Macrae
Mathias Walther
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP0301453A2 publication Critical patent/HUP0301453A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

A jelen találmány eletriptánt vagy gyógyszerészetileg elfogadhatósóját tartalmazó, orális beadásra alkalmas, szemcsés kompozícióra ésezt tartalmazó gyógyszerkészítményre vonatkozik, amelyek szigmoidgörbe szerinti, szabályozott hatóanyag-leadásra képesek. A szemcsésgyógyszer kompozíció eletriptánt vagy ennek gyógyszerészetilegelfogadható sóját tartalmazó magot foglal magában, amelytrimetilammónium-etilmetakrilát-csoportokat tartalmazó, egy vagy többakril-kopolimert magában foglaló, vízoldhatatlan, permeábilisbevonattal van ellátva. A találmány a szemcsés kompozícióelőállítására is vonatkozik. Ó
HU0301453A 2000-08-02 2001-07-18 Eletriptánt tartalmazó, szigmoid görbe szerinti, szabályozott hatóanyag-leadású, szemcsés kompozíció és eljárás az előállítására HUP0301453A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018968.8A GB0018968D0 (en) 2000-08-02 2000-08-02 Particulate composition
PCT/IB2001/001279 WO2002009675A1 (en) 2000-08-02 2001-07-18 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release

Publications (1)

Publication Number Publication Date
HUP0301453A2 true HUP0301453A2 (hu) 2003-08-28

Family

ID=9896843

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301453A HUP0301453A2 (hu) 2000-08-02 2001-07-18 Eletriptánt tartalmazó, szigmoid görbe szerinti, szabályozott hatóanyag-leadású, szemcsés kompozíció és eljárás az előállítására

Country Status (38)

Country Link
US (1) US20020034545A1 (hu)
EP (1) EP1365748B1 (hu)
JP (1) JP2004505034A (hu)
KR (1) KR20030024820A (hu)
CN (1) CN1630511A (hu)
AP (1) AP2001002233A0 (hu)
AR (1) AR030099A1 (hu)
AT (1) ATE308978T1 (hu)
AU (1) AU2001270932A1 (hu)
BG (1) BG107361A (hu)
BR (1) BR0112839A (hu)
CA (1) CA2417887C (hu)
CZ (1) CZ2003241A3 (hu)
DE (1) DE60114887T2 (hu)
EA (1) EA200300110A1 (hu)
EC (1) ECSP034451A (hu)
EE (1) EE200300051A (hu)
ES (1) ES2250429T3 (hu)
GB (1) GB0018968D0 (hu)
GT (1) GT200100149A (hu)
HR (1) HRP20030036A2 (hu)
HU (1) HUP0301453A2 (hu)
IL (1) IL153494A0 (hu)
IS (1) IS6649A (hu)
MA (1) MA26934A1 (hu)
MX (1) MXPA03000999A (hu)
NO (1) NO20030498D0 (hu)
NZ (1) NZ522976A (hu)
OA (1) OA12348A (hu)
PA (1) PA8523101A1 (hu)
PE (1) PE20020385A1 (hu)
PL (1) PL359847A1 (hu)
SK (1) SK1082003A3 (hu)
SV (1) SV2002000574A (hu)
TN (1) TNSN01115A1 (hu)
UY (1) UY26861A1 (hu)
WO (1) WO2002009675A1 (hu)
ZA (1) ZA200300868B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
US20060134012A1 (en) * 2002-12-16 2006-06-22 Symington John M Temporary pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
JP2006522790A (ja) * 2003-04-11 2006-10-05 ファイザー・インク エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
WO2005120456A2 (en) * 2004-06-09 2005-12-22 Pfizer Limited Formulation of eletriptan
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
KR20070115918A (ko) * 2005-01-31 2007-12-06 교린 세이야꾸 가부시키 가이샤 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
ES2434416T3 (es) 2005-08-10 2013-12-16 Add Advanced Drug Delivery Technologies, Ltd. Preparación oral con liberación controlada
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
EP2359830B1 (en) 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
US8137661B2 (en) 2007-07-25 2012-03-20 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infections using same
WO2011057676A1 (en) * 2009-11-16 2011-05-19 Evonik Röhm Gmbh A process for converting a solid (meth)acrylate copolymer into a dispersed form by means of a dispersing agent
FR3025425A1 (fr) * 2014-09-09 2016-03-11 Charleston Lab Inc Compositions pharmaceutiques
GB201716716D0 (en) * 2017-10-12 2017-11-29 Univ Of Hertfordshire Higher Education Corporation Method for coating particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release

Also Published As

Publication number Publication date
NZ522976A (en) 2004-11-26
UY26861A1 (es) 2002-02-28
CA2417887C (en) 2006-11-14
DE60114887D1 (de) 2005-12-15
TNSN01115A1 (fr) 2005-11-10
EP1365748B1 (en) 2005-11-09
EP1365748A2 (en) 2003-12-03
SK1082003A3 (en) 2004-09-08
DE60114887T2 (de) 2006-07-20
CN1630511A (zh) 2005-06-22
PA8523101A1 (es) 2002-08-26
NO20030498L (no) 2003-01-31
AR030099A1 (es) 2003-08-13
WO2002009675A1 (en) 2002-02-07
MXPA03000999A (es) 2003-06-09
AP2001002233A0 (en) 2001-09-30
JP2004505034A (ja) 2004-02-19
CZ2003241A3 (cs) 2004-02-18
ES2250429T3 (es) 2006-04-16
EE200300051A (et) 2004-10-15
EA200300110A1 (ru) 2003-06-26
CA2417887A1 (en) 2002-02-07
BR0112839A (pt) 2003-06-24
ZA200300868B (en) 2004-04-16
PE20020385A1 (es) 2002-05-11
IL153494A0 (en) 2003-07-06
WO2002009675A9 (en) 2003-07-10
PL359847A1 (en) 2004-09-06
NO20030498D0 (no) 2003-01-31
ATE308978T1 (de) 2005-11-15
US20020034545A1 (en) 2002-03-21
GT200100149A (es) 2002-06-25
BG107361A (bg) 2003-06-30
GB0018968D0 (en) 2000-09-20
SV2002000574A (es) 2002-12-02
MA26934A1 (fr) 2004-12-20
KR20030024820A (ko) 2003-03-26
AU2001270932A1 (en) 2002-02-13
OA12348A (en) 2004-03-19
ECSP034451A (es) 2003-03-10
HRP20030036A2 (en) 2003-04-30
IS6649A (is) 2002-12-05

Similar Documents

Publication Publication Date Title
HUP0301453A2 (hu) Eletriptánt tartalmazó, szigmoid görbe szerinti, szabályozott hatóanyag-leadású, szemcsés kompozíció és eljárás az előállítására
DE60117801D1 (de) Pharmazeutische zusammensetzung mit gesteuerter freigabe und verzögerter absorption
HUP0203204A2 (hu) Orális adagolási forma
HUP0201765A2 (hu) Maszkírozott ízű folyékony gyógyszerkészítmények
HUP0301887A2 (hu) Több részecskébżl álló gyógyszerforma, amely legalább két különbözżen bevont pelletformát tartalmaz
HUP0104039A2 (hu) Módosított hatóanyagleadású sokszemcsés készítmény
MY126555A (en) Oral pharmaceutical extended release dosage form
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
HUP0300373A2 (hu) Késleltetett leadású vitaminkészítmények és eljárás az előállításukra
HUP0202259A2 (hu) Szabályozott hatóanyag-leadású gyógyszer dózisforma, mely legalább egy időzített hatóanyag-leadást biztosít
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
GEP20053501B (en) Core Tablet for Controlled Release of Gliclazide after Oral Administration
AU2001291526A1 (en) Sustained release composition containing clarithromycin
ATE260645T1 (de) Agitationsunabhängige pharmazeutische multiple- unit-retardzubereitungen und verfahren zu ihrer herstellung
ATE430561T1 (de) Chronotherapeutische diltiazem formulierungen und deren verabreichung
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
DE60022332D1 (de) Ketoprofen mikrogranulat, verfahren zur herstellung desselben sowie pharmazeutische zusammensetzungen
HK1060691A1 (en) Ion-strength independent sustained release pharmaceutical formulation
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
DE69615400T2 (de) 5-asa enthaltendes orales arzneimittel mit modifizierter freisetzung sowie verfahren zur behandlung von darmerkrankungen
ATE302010T1 (de) Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus
UA74335C2 (uk) Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну
HUP0001234A2 (hu) Gyógyászati készítmény dexfenfluramin szabályzott (programozott) felszabadítására
CA2307547A1 (en) Chronotherapeutic diltiazem formulations and the administration thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees